BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1321@pharmaconomics
DTSTAMP:20260707T025901Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:MESO Phase 3 — Rexlemestrocel-L (estimated date)
DESCRIPTION:Phase 3 trial results for Rexlemestrocel-L in Chronic low back pain are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1345099/000134509926000051/exhibit991clbppivotaltri.htm\n\nTrack it: https://pharmaconomics.com/e/1321
URL:https://pharmaconomics.com/e/1321
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MESO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR